MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer

Clinical Biochemistry

Volumn 48, Issue 18, 2015, Pages 1235-1240

  Wieczorek, E ^a   Jablonowski, Z ^b   Tomasik, B ^b   Konecki, T ^b   Jablonska, E ^a   Gromadzinska, J ^a   Fendler, W ^b   Sosnowski, M ^b   Wasowicz, W ^a   Reszka, E ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bladder cancer recurrence; Gene expression; MMP; TIMP; VEGF

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GELATINASE A GENE; GELATINASE B GENE; GENE; GENE EXPRESSION; HUMAN; INTERSTITIAL COLLAGENASE GENE; MALE; PRIORITY JOURNAL; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TISSUE INHIBITOR OF METALLOPROTEINASE 3 GENE; VASCULOTROPIN A GENE; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; GENETICS; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SMOKING; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MMP1 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949086903     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.07.021     Document Type: Article

References (39)

1. Kassouf W., Swanson D., Kamat A.M., Leibovici D., Siefker-Radtke A., Munsell M.F., et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J. Urol. 2006, 175:2058-2062.
2. Prout G.R., Wesley M.N., Yancik R., Ries L.A., Havlik R.J., Edwards B.K. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 2005, 104:1638-1647.
3. Noel A., Gutierrez-Fernandez A., Sounni N.E., Behrendt N., Maquoi E., Lund I.K., et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front. Pharmacol. 2012, 3:140.
4. Decock J., Thirkettle S., Wagstaff L., Edwards D.R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 2011, 15:1254-1265.
5. Goel H.L., Mercurio A.M. Vegf targets the tumour cell. Nat. Rev. Cancer 2013, 13:871-882.
6. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 2000, 55:15-35.
7. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12:233.
8. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
9. Ramon de Fata F., Ferruelo A., Andres G., Gimbernat H., Sanchez-Chapado M., Angulo J.C. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer. Actas Urol. Esp. 2013, 37:480-488.
10. Szarvas T., vom Dorp F., Erguen S., Ruebben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol. 2011, 8:241-254.
11. Kanayama H., Yokota K., Kurokawa Y., Murakami Y., Nishitani M., Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998, 82:1359-1366.
12. Naruo S., Kanayama H., Aki M., Kagawa S. Gene expressions of type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers. Nihon Hinyokika Gakkai zasshi Jpn. J. Urol. 1993, 84:841-850.
13. Quentin T., Schlott T., Korabiowska M., Kathe N., Zoller G., Glaser F., et al. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res. 2004, 24:2745-2756.
14. Kopparapu P.K., Boorjian S.A., Robinson B.D., Downes M., Gudas L.J., Mongan N.P., et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013, 33:2381-2390.
15. Zaravinos A., Volanis D., Lambrou G.I., Delakas D., Spandidos D.A. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol. Rep. 2012, 28:1159-1166.
16. Wallard M.J., Pennington C.J., Veerakumarasivam A., Burtt G., Mills I.G., Warren A., et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br. J. Cancer 2006, 94:569-577.
17. Witjes J.A., Compérat E., Cowan N.C., De Santis M., Gakis G., Lebret T., et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 2014, 65:778-792.
18. Muller P.Y., Janovjak H., Miserez A.R., Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002, 32:1-7.
19. Simon P. Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics 2003, 19:1439-1440.
20. Deryugina E.I., Quigley J.P. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015, 44-46:94-112.
21. Hofmann H.S., Hansen G., Richter G., Taege C., Simm A., Silber R.E., et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin. Cancer Res. 2005, 11:1086-1092.
22. Shao W., Wang W., Xg Xiong, Cao C., Yan T.D., Chen G., et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J. Surg. Oncol. 2011, 104:841-846.
23. Cheng C.W., Yu J.C., Wang H.W., Huang C.S., Shieh J.C., Fu Y.P., et al. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin. Chim. Acta 2010, 411:234-241.
24. Fan S., Wei Q., Li M., Zhang L., Liang Q. Expression and clinical significance of MMP-2, MMP-9, TIMP-1, and TIMP-2 in breast carcinoma. Ai Zheng Chin. J. Cancer 2003, 22:968-973.
25. Liew C.C., Ma J., Tang H.C., Zheng R., Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 2006, 147:126-132.
26. Xu K.X., Hou S.K., Du Z.J. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma. Chin. Med. J. 2002, 115:743-745.
27. Hagemann T., Gunawan B., Schulz M., Füzesi L., Binder C. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur. J. Cancer 2001, 37:1839-1846.
28. Oberg A., Hoyhtya M., Tavelin B., Stenling R., Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000, 20:1085-1091.
29. Crew J.P., Obrien T., Bradburn M., Fuggle S., Bicknell R., Cranston D., et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997, 57:5281-5285.
30. Choi Y.D., Cho N.H., Ahn H.S., Cho K.S., Cho S.Y., Yang W.J. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J. Urol. 2007, 177:1174-1178.
31. Koebnick C., Michaud D., Moore S.C., Park Y., Hollenbeck A., Ballard-Barbash R., et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol. Biomark. Prev. 2008, 17(5):1214-1221.
32. Holick C.N., Giovannucci E.L., Stampfer M.J., Michaud D.S. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int. J. Cancer 2007, 120(1):140-146.
33. Ecke T.H., Schlechte H.H., Gunia S., Lenk S.V., Loening S.A. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations 2008, 26(5):470-473.
34. Fauconnet S., Bernardini S., Lascombe I., Boiteux G., Clairotte A., Monnien F., et al. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol. Rep. 2009, 21:1495-1504.
35. Angulo J.C., Ferruelo A., Rodriguez-Barbero J.M., Nunez C., de Fata F.R., Gonzalez J. Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood. Actas Urol. Esp. 2011, 35:127-136.
36. Hara I., Miyake H., Hara S., Arakawa S., Kamidono S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol. 2001, 165:1769-1772.
37. Shishodia S., Potdar P., Gairola C.G., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003, 24:1269-1279.
38. Vasala K., Kuvaja P., Turpeenniemi-Hujanen T. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumor Biol. 2008, 29:279-286.
39. Allaparthi S., Balaji K.C. Bladder tumors: molecular aspects and clinical management. Treatment of Low-grade Bladder Tumors 2014, 237-252. (Chapter 12).